|Bid||150.00 x 200|
|Ask||168.80 x 500|
|Day's Range||148.58 - 152.07|
|52 Week Range||71.46 - 167.86|
|PE Ratio (TTM)||145.30|
|Earnings Date||Oct 23, 2017 - Oct 27, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||178.21|
They've got successful drugs. They're profitable. All these biotechs need to become huge is a little luck and time.
Vertex is nearing the end of its journey in cystic fibrosis with likely approval of a triple pill in the next couple of years.
Vertex Pharmaceuticals Incorporated today announced that management will present at the Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology on Wednesday, September 27, 2017 at 11:30 a.m.